Fig. 1.

Amplification and co-amplification of LANCL2 and EGFR were frequent in GBM specimens of TCGA database, and LANCL2 amplification were associated with poor OS in younger GBM patients. A, B Genetic alteration frequencies of LANCL2 and EGFR in 32 different cancers of TCGA Pan-Cancer Atlas database. The diagrams showed the top 22 cancers with the highest frequencies. C Amplification frequencies of LANCL2 and EGFR in two TCGA studies of Glioblastoma Multiforme (n = 592) and Brain Lower Grade Glioma (n = 514). D Amplification frequencies of LANCL2 and EGFR in different pathological types of gliomas. E Co-amplification frequencies of LANCL2 and EGFR in total or EGFR-amplified GBM samples. F Chi-square test (Fisher’s exact test) showed the CNVs of LANCL2 and EGFR in GBM were significantly associated. G The top 10 genes with the highest amplification frequencies in LANCL2- or EGFR-amplified GBM samples. H Chi-square test showed that CNVs of LANCL2 and EGFR were significantly correlated with IDH1/2 mutation status in GBM. I Forest plot showing the univariate analysis for OS in GBM patients of TCGA database. J Forest plot showing the univariate analysis for OS in younger (< 60 years) GBM patients of TCGA database. P values and hazard ratios were determined by log-rank test